Get in touch

What we can help with

Three kinds of message get a reply. First, factual corrections — if something here contradicts the published trial record, it should be fixed, and the source credited. Second, missing citations — if a published trial, structural study, or sponsor disclosure has been overlooked, it can be added. Third, reader questions about the record itself: what a number means, where a finding comes from, how a paper handled a particular subgroup.

Replies usually land within a few weekdays. Every message is read; not every message is answered (compliments are received with thanks and quietly absorbed).

What we cannot help with

This casebook cannot offer medical advice, weigh a personal situation, suggest a dose, judge whether a particular reader is a candidate for a particular molecule, or refer to a prescriber. It is editorial, not clinical.

It also can't help anyone obtain retatrutide. The molecule is investigational; there is no commercial product; the site sells nothing, sources nothing, and refers to no supplier. Requests of that kind are declined, politely and without exception.

Contact form

The form below takes a name, an email, an optional subject, and a message. No analytics ride on a submission beyond a simple anti-spam token. Messages reach the editor by email; nothing is retained past the working conversation, and nothing is shared.

If email is easier, the address is editor@retatrutideprescribed.com — write directly, and please include any URLs or citations relevant to your note so the right page is easy to find.

A final note

This casebook does not give medical advice; the disclaimer at the foot of every page is the contract. If you are weighing a clinical decision, talk with a qualified clinician who has your full history, your current medications, and the regulatory picture as it stands where you are, when you read this. The published trial record is a place to start an informed conversation — never a substitute for one.